[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Recruiting · NCT06120049 · Registry updated 2025-02-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD | Alzheimer disease, Lewy body dementia, Parkinson disease, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cognitive disorder, dementia, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, psychiatric disorder, synucleinopathy, tauopathy, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2025-02-06 | NCT06120049 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fund for Scientific Research, Flanders, Belgium | 8 |
| KU Leuven | 110 |
| prof. dr. Koen Van Laere | 2 |
| Universitaire Ziekenhuizen KU Leuven | 262 |
| University Hospital, Ghent | 163 |
2 results · Page 1 of 1